Oncopeptides announced today it is pulling its myeloma drug Pepaxto (melphalan flufenamide) from the market after failing a confirmatory trial. Pepaxto won accelerated approval in February, but in July, the FDA alerted patients and healthcare professionals that the confirmatory trial was halted. Oncopeptides said it will work with the FDA to continue to make Peptaxo available to patients currently receiving the drug.

Read more here:



Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.